Problems associated with the use of thyrogen in patients with a thyroid gland

New England Journal of Medicine

Volumn 359, Issue 16, 2008, Pages 1738-1739

  Magner, James ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN;

AGED; CASE REPORT; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTHYROIDISM; LETTER; NODULAR GOITER; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWELLING; THYROID CANCER; THYROID GLAND; THYROIDECTOMY;

EID: 54049087014     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0807896     Document Type: Letter

References (4)

1. Juweid M, O'Dorisio T, Milhem M. Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation. N Engl J Med 2008;359:1295-7.
2. Nielsen VE, Bonnema SJ, Hegedüs L. The effects of recombinant human thyrotropin in normal subjects and patients with goiter. Clin Endocrinol (Oxf) 2004;61:655-63.
3. Magner JA, Kipnes MS, Kloos RT, Law BM, Braverman LE. Cardiac effects of Thyrogen (rhTSH) in multinodular goiter (MNG) patients: a cautionary note. Presented at the 77th annual meeting of the American Thyroid Association, Phoenix, AZ, October 11-15, 2006. abstract.
4. Robbins RJ, Driedger A. Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:1121-30.